Related by context. All words. (Click for frequent words.) 67 REBETOL combination therapy 67 DORIBAX 66 SinuNase TM 66 ACTEMRA TM 66 PEGINTRON TM 65 sorafenib tablets 65 Peginterferon alfa 2b 65 methylnaltrexone bromide 65 refractory chronic lymphocytic 65 TYGACIL 64 Ranolazine 64 Orphan Drug designations 64 acyclovir Lauriad R 64 Pivotal Phase III 64 complicated intra abdominal 64 ARCOXIA 64 GTC recombinant human 64 PROVENGE ® 63 TORISEL 63 trastuzumab DM1 T DM1 63 Kuvan R 63 GATTEX TM 63 aztreonam 63 Noxafil 63 Cloretazine ® 63 vapreotide acetate 63 Rasilez HCT 63 severe hypercholesterolemia 63 hoFH 63 Civacir 63 CRMD# 63 PDX pralatrexate 63 Panzem R 63 diarrhea predominant irritable 63 TORISEL TM 63 SEBIVO 62 Cellegesic 62 HCV SPRINT 62 REG1 Anticoagulation System 62 Phenoptin 62 Marketing Authorisation Application 62 STELARA TM 62 Veronate 62 FOLOTYN ® 62 histamine dihydrochloride 62 Allovectin 7 r 62 Positive Opinion 62 MAA submission 62 HepaGam B TM 62 Complicated Skin 62 molecular imaging radiopharmaceutical 62 MAGE A3 ASCI 62 sorafenib Nexavar 62 phase IIb clinical 62 dihydrochloride Tablets 62 SPRYCEL ® 62 Known hypersensitivity 62 NDA Submission 62 catheter occlusion 62 Aryplase 61 alvimopan 61 cutaneous T 61 LibiGel ® 61 lenalidomide Revlimid R 61 liver resection surgeries 61 investigational hepatitis B 61 dasatinib Sprycel ® 61 GATTEX ® 61 NOXAFIL 61 Amrubicin 61 CAELYX 61 Sebivo 61 LEUKINE 61 Methylnaltrexone 61 lintuzumab SGN 61 Targretin capsules 61 Dalbavancin 61 balsalazide disodium 61 Initiate Phase 61 Esbriet ® 61 StaphVAX R 61 ezogabine 61 SinuNase ™ 61 relapsed MM 61 Diabetic Macular Edema 61 oral ridaforolimus 61 Personalized Immunotherapy 61 forodesine 61 delivers fluocinolone acetonide FA 61 TEMODAL 61 Pivotal Trial 61 cSSSI 61 Plicera 61 DIFICID ™ 61 rilonacept 61 Kepivance 61 PROVENGE sipuleucel T 61 histone deacetylase HDAC inhibitor 61 Pivotal Phase 61 Certican 61 Silodosin 61 Biologic License Application BLA 61 intravenous iclaprim 61 selective A2A adenosine receptor 61 Aurexis 61 Crofelemer budesonide foam 61 Mylan Receives Approval 61 investigational antiplatelet agent 61 human C1 inhibitor 61 Elagolix 61 Zavesca R 61 ORENCIA ® 61 Xcytrin R 61 LEVAQUIN 61 refractory Hodgkin lymphoma 61 GTC recombinant form 61 Marketing Authorization Applications 61 Fludara ® 61 Cethromycin 61 CYT# potent vascular disrupting 61 Phase III Clinical Trial 61 sapropterin dihydrochloride 61 toenail onychomycosis 61 Meets Primary Endpoint 61 sunitinib malate 61 Panzem R NCD 61 Evoltra ® 61 evaluating tivozanib 61 Angiox ® 61 Faropenem 61 R lenalidomide 61 FIRAZYR 60 Receives Orphan Drug Designation 60 Pivotal Study 60 Rhucin R 60 Fibrillex TM 60 IMiDs ® compound 60 Initiates Enrollment 60 Velcade bortezomib 60 Achieves Primary Endpoint 60 Initiates Phase III 60 Cancidas 60 JOULFERON 60 arsenic trioxide injection 60 Receives Marketing Authorization 60 Chemophase 60 BYETTA ® 60 Drug Eluting Stent System 60 Phase IIb Trial 60 oxymorphone ER 60 Soriatane 60 dextromethorphan quinidine 60 Bendamustine 60 atypical Hemolytic Uremic Syndrome 60 buccal tablets 60 Oracea ® 60 Lambert Eaton Myasthenic 60 Clolar ® 60 PNP inhibitor 60 TLK# 60 cisplatin gemcitabine 60 albinterferon alfa 2b 60 Telavancin 60 Phase 2a clinical trials 60 candidate XP# 60 TELCYTA 60 Entereg R 60 Severe Sepsis 60 including eniluracil ADH 60 elotuzumab 60 Glufosfamide 60 highly purified pasteurized 60 interferon gamma 1b 60 Tamibarotene 60 induced macular edema 60 Tasigna nilotinib 60 Ciclesonide 60 BENLYSTA ® 60 Yondelis ® 60 QNEXA ® 60 XL# anticancer compounds 60 Zenvia ™ 60 reslizumab 60 Phase Ib study 60 AVASTIN 60 Marketing Authorization Application 60 tazobactam 60 Solid Tumors criteria 60 systemic immunosuppressive drugs 60 cSSTI 60 Zenpep 60 Second Pivotal Phase 60 By JENNIFER LEARN 60 PEGylated interferon beta 1a 60 Bezielle 60 Omacetaxine 60 virus HCV protease inhibitor 60 Vidaza azacitidine 60 PEG PAL 60 Nabi HB Intravenous 60 liposomal formulation 60 Clevudine 60 topically applied SEPA 60 multicenter Phase III 60 sitaxsentan sodium 60 Mycamine 60 phase IIb study 60 JZP 60 Tracleer R 60 ALN TTR 59 REVLIMID R 59 ONGLYZA ™ 59 successfully commercialize Iluvien 59 haematologic 59 GATTEX ™ 59 Locteron ® 59 Receives Orphan Drug 59 AzaSite Plus 59 dose cohort 59 UPLYSO 59 Completes Patient Enrollment 59 Cloretazine 59 Nexavar sorafenib 59 Afatinib 59 levocetirizine 59 Tekturna HCT 59 ARIXTRA R 59 vernakalant hydrochloride 59 HoFH 59 oral cladribine 59 OvaRex ® MAb 59 Combidex 59 Golimumab 59 Receives Positive Opinion 59 Tekamlo 59 Cimzia R 59 generation purine nucleoside 59 Generx TM 59 pain palliation 59 Initiated Phase 59 PREOS R 59 PHX# 59 cinacalcet HCl 59 treat opioid induced 59 ELACYT 59 Nivestim 59 Alitretinoin 59 visit www.dobimedical.com 59 CoFactor 59 TRANSDUR ™ 59 BARACLUDE R 59 Allovectin 7 R 59 teduglutide 59 Simulect 59 JAK2 Inhibitor 59 Vitrasert R 59 anidulafungin 59 SUCCEED trial 59 Allovectin 7 ® 59 REVLIMID lenalidomide 59 CLARITY study 59 Pirfenidone 59 PrevOnco ™ 59 Mg Uk 59 IL# PE#QQR 59 ongoing Phase 1b 59 Increlex R 59 Ceftobiprole 59 hypereosinophilic syndrome 59 Rhucin ® recombinant 59 HuMax CD4 59 ThermoDox R 59 Dapagliflozin 59 Basilea Toctino R 59 Prospective Randomized 59 pomalidomide 59 Androxal ® 59 Onalta ™ 59 Dasatinib 59 DexaSite 59 briakinumab 59 aflibercept 59 Romiplostim 59 ARIXTRA 59 refractory cutaneous T 59 ZOLINZA 59 NEUPOGEN 59 KYNAPID 59 Natroba 59 mesylate tablets 59 Tygacil 59 PANVAC VF 59 Expanded Indication 59 Zenvia Phase III 59 FDA Accepts 59 SUTENT ® 59 Phase III Pivotal 59 OMNARIS HFA 59 Prodarsan R 59 Torisel 59 BCG refractory 59 Vascular Disrupting Agent 59 Accelerated Approval 59 thalidomide Thalomid 59 Teysuno 59 Adalimumab 59 Dupuytren Contracture 59 Vascular Wrap TM 59 FACTIVE R gemifloxacin 59 Alocrest 59 GALNS 59 hepatitis C HCV 59 mGluR5 negative 59 relapsed refractory multiple myeloma 59 MEK Inhibitor 59 FASLODEX 59 MelaFind R 59 Dacogen injection 58 Amigal TM 58 Nexavar tablets 58 phase Ib 58 ATryn ® GTC recombinant 58 Xolegel 58 clevidipine 58 Ixempra 58 Somatuline Depot 58 Privigen 58 metastatic malignant 58 PrevOnco 58 Retacrit 58 RoACTEMRA 58 Phase IIb Clinical Trial 58 Submits NDA 58 Humenza 58 Actemra tocilizumab 58 Focetria 58 Liprotamase 58 Icatibant 58 receptor tyrosine kinase inhibitor 58 Nexavar ® 58 Onrigin TM 58 Frova ® 58 treat chronic sinusitis 58 SNT MC# 58 Aflibercept 58 CIMZIA ™ 58 ospemifene 58 Kit CD# positive 58 irinotecan containing 58 Dyloject TM 58 casopitant 58 LUVENIQ 58 FUSILEV ® 58 Kuvan sapropterin dihydrochloride 58 CONBRIZA 58 Brentuximab Vedotin SGN 58 treatment naive genotype 58 trastuzumab Herceptin R 58 Pentacel vaccine 58 TAXUS Element Stent System 58 Raptiva ® 58 HCV RESPOND 2 58 CIP TRAMADOL ER 58 Onalta 58 Tesamorelin 58 sunitinib Sutent 58 OMNARIS 58 Genasense R oblimersen 58 Fast Track Status 58 Ondansetron Injection USP 58 desvenlafaxine succinate 58 EOquin 58 pregabalin Lyrica 58 NEUPOGEN R 58 nephropathic cystinosis cystinosis 58 Marketing Authorization Application MAA 58 Besivance 58 Anturol TM 58 Allovectin 7 58 PREOS 58 TRANSDUR ® 58 Phase 2b Clinical Trial 58 Archexin 58 investigational pharmacologically unique 58 Hedgehog Pathway Inhibitor 58 xanthine oxidase inhibitor 58 Fondaparinux 58 Chronic Idiopathic Constipation 58 Phase III Clinical Trials 58 Randomized Phase 58 BrachySil TM 58 RANK Ligand inhibitor 58 Phase Ib II 58 MabCampath 58 adalimumab Humira 58 Triapine R 58 Dacogen TM 58 Vfend 58 Ganite ® 58 COMFORT II 58 CABP 58 Xanafide 58 Fortigel 58 Application MAA 58 oral deforolimus 58 pemetrexed Alimta 58 Aztreonam 58 novel histone deacetylase 58 OMP designation 58 APPRAISE 58 Vicinium TM 58 SPRIX ® 58 Iluvien ® 58 alvespimycin 58 Completes Enrollment 58 Jevtana 58 confirmatory clinical 58 Cimzia ® 58 octreotide implant 58 Study Evaluating 58 pancreatic enzyme replacement 58 Cimzia ® certolizumab pegol 58 epoetin alpha 58 Metastatic Colorectal Cancer 58 MyVax R 58 lucinactant 58 Hematide ™ 58 Prostate AdenoCarcinoma Treatment 58 VIVITROL ® 58 Fluconazole 58 nasal calcitonin product 58 Somatuline R Autogel R 58 BLA filing 58 Azedra 58 Oracea TM 58 Premarket Approval Application 58 Telatinib 58 containing granisetron 58 granted Ortec 58 Vertex telaprevir 58 Onbrez Breezhaler 58 Arzerra TM 58 kidney urologic 58 RSD# iv 58 primary hypercholesterolemia 58 XAGRID 58 methylnaltrexone 58 RAPTIVA 58 Rhucin ® 58 Begins Dosing 58 Firazyr 58 TELINTRA R 57 Tibotec Therapeutics division 57 Androxal TM 57 thetreatment 57 ATACAND 57 IV APAP 57 Raptiva R 57 sNDAs 57 post operative ileus 57 idursulfase 57 Prolongs Survival 57 ZEGERID Capsules 57 Trial Evaluating 57 LymphoStat B belimumab 57 ceftobiprole 57 Topline Results 57 Durezol TM 57 Febuxostat 57 Phase #/#a trial 57 Eloxatin ® 57 Acetavance TM 57 ganetespib 57 Multiple Ascending Dose 57 Maleate 57 Acute Radiation Syndrome ARS 57 Toctino R 57 By JAMAAL ABDUL 57 systemic anaplastic large 57 Genasense ® 57 Ocrelizumab 57 QNEXA 57 eosinophilic asthma 57 synthetic retinoid 57 GW# [003] 57 PROMACTA 57 Eculizumab 57 peginesatide 57 Filgrastim 57 pseudobulbar affect PBA 57 acyclovir Lauriad ® 57 BRIM2 57 Keryx Biopharma 57 Ambrisentan 57 CERVARIX R 57 trabectedin 57 R vitespen 57 vosaroxin 57 Cladribine Tablets 57 Phase 1a clinical 57 Proellex TM 57 IIa trial 57 Initiates Phase II 57 ELADUR ™ 57 Amigal 57 Edurant 57 RELOVAIR ™ 57 Granted Orphan Drug 57 Phase 2b study 57 supplemental Biologics License Application 57 dirucotide MBP# 57 REMICADE ® 57 recurrent glioblastoma multiforme 57 rHuPH# recombinant human 57 Bayer HealthCare Onyx Pharmaceuticals 57 Patient Enrollment 57 Catena ® 57 SYCREST 57 oxypurinol 57 Syndrome LEMS 57 Flutiform ™ 57 registrational 57 Xyrem ® 57 lymphoid malignancies 57 Omigard TM 57 AA amyloidosis 57 GAMMAGARD 57 ADP receptor antagonist 57 Phase 1b Clinical Trial 57 blinded randomized placebo controlled 57 Orphan Status 57 Orphan Designation 57 rALLy clinical trial 57 Phase #b/#a clinical 57 dependent kinase inhibitor 57 Trobalt 57 Acute Ischemic Stroke 57 amifampridine phosphate 57 Cetrorelix 57 Sutent sunitinib malate 57 PREZISTA r 57 LEVADEX TM 57 Combination REOLYSIN R 57 Firdapse TM amifampridine phosphate 57 CALGB # [002] 57 prGCD 57 relapsing remitting MS RRMS 57 human antithrombin 57 Chronic Heart Failure 57 OAB overactive bladder 57 ISTODAX 57 histone deacetylase inhibitor 57 ZALBIN 57 Phase IIb trials 57 atypical antipsychotic medication 57 ATryn ® 57 orphan medicinal product 57 HepeX B 57 Fibrin Pad 57 Albuferon TM 57 risedronate sodium tablets 57 tocilizumab 57 Hiberix 57 candidate brentuximab vedotin 57 ZYBRESTAT TM 57 capsule formulation 57 Product Characteristics 57 Surfaxin LS 57 HepaSphere 57 phase IIa 57 DASISION 57 paliperidone palmitate 57 metastatic castration resistant 57 Doxil ® 57 FRDA 57 Velaglucerase Alfa 57 Orphan Drug status 57 PRECISE Trial 57 Bosutinib 57 NOVARTIS 57 Hsp# Inhibitor 57 Femara letrozole 57 LymphoStat B TM 57 Phase IIb clinical trials 57 exenatide injection 57 Initiates Clinical 57 TRANSDUR Sufentanil 57 Orathecin 57 Recombinant Human 57 alefacept 57 abatacept Orencia 57 Phase IIB 57 FavId 57 Onrigin 57 Marketing Authorisation 57 Announces Tentative Approval 57 TACI Ig 57 Keppra ® levetiracetam 56 SmPC 56 regadenoson 56 sNDA submission 56 decitabine 56 N acetylgalactosamine 6 56 Plenaxis R 56 LUX Lung 56 AGILECT R 56 Cutaneous T 56 Fodosine 56 fidaxomicin 56 personalized cellular immunotherapy 56 Vion Pharmaceuticals 56 Phase 2a Clinical Trial 56 Eraxis 56 KRN# 56 radiation sensitizer 56 PROMUS Element Stent System 56 PegIntron 56 Sprycel dasatinib 56 budesonide foam 56 zalutumumab 56 Hepatocellular Carcinoma HCC 56 ORENCIA R 56 Immunotherapeutic 56 Taro Receives 56 ketolide antibiotic 56 Sulonex TM 56 fosbretabulin 56 guanfacine extended release 56 phase IIa clinical 56 RIGScan CR 56 Vibativ 56 Marketing Authorization 56 Augment Injectable 56 agalsidase alfa 56 Sporanox 56 cardio renal 56 Japanese Encephalitis Vaccine 56 BCX# 56 Avelox 56 Glybera R 56 Nasdaq PGNX today 56 CERVARIX 56 ABILIFY R 56 Phase Ib 56 Genasense ® oblimersen 56 novel emulsion formulation 56 Phase 1b dose escalation 56 gefitinib Iressa 56 Anthim 56 Luveniq 56 V Everolimus Eluting Coronary 56 Entereg TM 56 Gonal f 56 Phase Ib Clinical Trial 56 dextofisopam 56 stage IIIB 56 prucalopride 56 paclitaxel poliglumex 56 BLP# Liposome Vaccine 56 rotigotine transdermal patch 56 bevirimat Study 56 Medicinal Products EMEA 56 PEG IFN 56 intravesical infusion therapy 56 Phase IIIb clinical 56 DAYTRANA TM 56 OMAPRO ™ 56 metastatic RCC 56 modified glutathione analog 56 Vectibix panitumumab 56 NASDAQ ISTA 56 Phase IIa clinical trials 56 HepeX B TM 56 Staccato loxapine 56 INCB# [001] 56 YONDELIS R 56 donepezil rivastigmine 56 Nebido 56 OPAXIO 56 neovascular age 56 Loramyc 56 Cimzia TM 56 EOquin TM 56 Urocidin TM 56 efalizumab 56 sodium Injection 56 Ramelteon 56 metastatic neuroendocrine tumors 56 rasagiline tablets 56 EFAPROXYN 56 Bazedoxifene 56 ZYBRESTAT fosbretabulin 56 Hepatic 56 hyaluronidase enzyme 56 Late Breaker 56 AstraZeneca Symbicort 56 Phase 2a trial 56 ADVANCE PD 56 Soliris TM eculizumab 56 Qutenza TM 56 HBeAg negative patients 56 Interferon alpha 56 fallopian tube cancers 56 Severe VOD 56 MIVI III 56 dalbavancin 56 Centralized Procedure 56 ofatumumab HuMax CD# 56 relapsed multiple myeloma 56 Pegintron 56 eribulin mesylate 56 midstage clinical 56 fluoroquinolone antibiotic 56 GTC NASDAQ GTCB 56 Sumatriptan Succinate 56 Firdapse 56 Bone Graft 56 Traficet EN 56 Initiates Phase 2b 56 Polyphenon ® E 56 Premarket Approval PMA 56 metastatic castrate resistant 56 Æterna Zentaris 56 Hedgehog antagonist 56 evaluating REVLIMID 56 Cardiotoxicity 56 CEQ# 56 SUPPRELIN R LA 56 tanespimycin 56 ularitide 56 Restanza 56 Silenor ® doxepin 56 Azilect ® 56 First Patient Enrolled 56 thymalfasin 56 KRYSTEXXA TM pegloticase 56 Investigational Treatment 56 BR.# 56 budesonide MMX Phase III 56 Tindamax 56 Calcium Acetate 56 designated HVTN 56 Hepatocellular Carcinoma 56 HSCT 56 Alvesco R 56 tiapamil 56 CAMPATH R 56 orphan designation 56 oral picoplatin 56 THALOMID 56 Arixtra 56 Onconase 56 POSIDUR TM 56 Zevtera TM 56 Generx ™ 56 AA Amyloidosis 56 Investigational Compound 56 ATryn R 56 Genasense R 56 Esbriet pirfenidone 56 Oral Calcitonin 56 Thalidomide Pharmion 56 BRIM3 56 Advanced Melanoma 56 IXEMPRA 56 Microwave Ablation System 56 Decentralized Procedure 55 Advanced Renal Cell 55 huN# DM1 55 ZEGERID Chewable Tablets 55 MGCD# [001] 55 Japanese Encephalitis vaccine 55 gemcitabine Gemzar ® 55 phase IIIb 55 PFO migraine 55 Omigard 55 Darunavir 55 darbepoetin alfa Aranesp 55 lomitapide 55 Submits Supplemental 55 BENICAR 55 Phase Ib clinical trials 55 SILENOR TM 55 axitinib 55 Testosterone MDTS ® 55 Azacitidine 55 relapsing multiple sclerosis 55 HCV Protease Inhibitor 55 mycophenolate mofetil MMF 55 Ceflatonin ® 55 Renal Cell Carcinoma RCC 55 Celebrex celecoxib 55 OLpur TM H2H 55 Phase III Trial 55 R sipuleucel T 55 Mylotarg 55 polycythemia vera essential thrombocythemia 55 recurrent metastatic 55 steroid refractory GvHD 55 registrational Phase 55 Zarnestra 55 pharmacokinetic PK study 55 indiplon capsules 55 Orphan Drug Status 55 Myelodysplastic Syndromes MDS 55 Diamyd r 55 Application BLA 55 Alvesco ® 55 etanercept Enbrel 55 Tracleer ® bosentan 55 GARDASIL ® 55 talactoferrin 55 Metricath Gemini 55 Premarket Approval 55 antibiotic candidate Ramoplanin 55 somatostatin analog 55 Superficial Femoral Artery 55 APEX AMI 55 Novartis VIRT X 55 Frovatriptan 55 custirsen 55 octagam ® 55 Oral Solution 55 Belimumab 55 Phase 2b clinical 55 Egrifta 55 compound INCB# 55 IIb clinical trial 55 Aflunov 55 Cefprozil 55 Vimpat R 55 SEROQUEL XR 55 abatacept 55 REYATAZ R 55 lymphoma CTCL 55 Cardium Therapeutics TM 55 Phase III randomized controlled 55 Mimpara 55 Frozen Shoulder syndrome Adhesive 55 Ceflatonin 55 Pixuvri 55 Ofatumumab 55 Afinitor ® 55 Luveris 55 NASDAQ AVNR 55 Restoraderm R 55 APF# Phase 55 UCB Cimzia 55 familial amyloidotic polyneuropathy FAP 55 plus COPEGUS 55 please visit www.advaxis.com 55 vemurafenib 55 Zalbin 55 dirucotide 55 Acute Coronary Syndromes ACS 55 evaluating picoplatin 55 Etravirine 55 IIa clinical 55 RECIST Response Evaluation Criteria 55 solifenacin succinate 55 Mepact 55 Initiate Phase II 55 Kristalose R 55 Pivotal Clinical Trial 55 Motavizumab 55 Cloretazine R VNP#M 55 Regeneron Pharma 55 Phase 2b Trial 55 Alzhemed TM 55 Carfilzomib 55 ATIR 55 YERVOY 55 CaPre TM 55 ALN RSV# 55 EVIZON TM 55 anakinra 55 hepatitis B immunoglobulin 55 Medidur TM FA 55 PDUFA Date 55 FDA Orphan Drug 55 Relistor 55 Bicifadine 55 cutaneous T cell 55 Successfully Completes Phase 55 #D#C# 55 Taxotere ® 55 randomized controlled Phase 55 Initiate Phase III 55 Exforge HCT 55 LHRH antagonist 55 Alfimeprase 55 anti inflammatory NSAID 55 Acute Decompensated Heart Failure 55 Zavesca 55 Receives Approvable Letter 55 Inhalation Powder 55 IMA# 55 hepatocellular carcinoma HCC 55 PATHFINDER R 55 pralatrexate injection folate analogue 55 Demonstrates Sustained 55 QVAR ® 55 Decentralized Procedure DCP 55 Clinical Trial Evaluating 55 CG# [003] 55 PLK1 SNALP 55 Phase III clinical 55 KNS # 55 SPL# Gel vaginal microbicide 55 LIALDA 55 Angiox R 55 REMOXY NDA 55 evaluating satraplatin 55 unique alkylating agent 55 ANDA Filing 55 Perifosine 55 NSABP B 55 Vivaglobin 55 Phase Ib IIa 55 REMICADE infliximab 55 adjuvant GIST 55 Solazed ™ 55 XIAFLEX ® 55 leading oral taxane 55 Remicade infliximab 55 Non inferiority 55 XEOMIN 55 AOP Orphan 55 refractory metastatic colorectal cancer 55 Gentamicin Surgical Implant 55 Marketing Authorisation Application MAA 55 ongoing Phase IIIb 55 TRO# 55 ELIQUIS 55 SABER ™ 55 XIAFLEX ™ 55 Rapaflo 55 Soft Tissue Sarcoma 55 mitogen activated ERK kinase 55 Phase IIIb 55 evaluating Prochymal 55 biostatistical analysis 54 Prodarsan 54 candidate Zenvia 54 rALLy trial 54 CRVO 54 Vaccine Diphtheria CRM# Protein 54 Ganite R 54 NASDAQ CXSP announced 54 placebo controlled Phase III 54 FDA Approvable Letter 54 metastatic renal cell carcinoma 54 vismodegib 54 C1 Inhibitor 54 evaluating mipomersen 54 Phase IIIb study 54 ThermoDox ® clinical 54 Biologics Licensing 54 recurrent metastatic ovarian cancer 54 mTOR inhibitor 54 AVOREN 54 Preotact 54 ® decitabine 54 Trandolapril 54 ELADUR 54 antifungal agent 54 metastatic sarcomas 54 Plenaxis TM 54 glufosfamide 54 Budesonide 54 bevacizumab Avastin 54 visit smith.com 54 Orapred ODT 54 MERLIN TIMI 54 Muraglitazar 54 Microalbuminuria 54 Loramyc R 54 Azathioprine 54 Solid Tumors 54 DC Bead 54 L MTP PE 54 product platforms AZX# 54 β blockers 54 evaluating T DM1 54 Emollient Foam 54 Angiox 54 phase IIb trial 54 registrational trial 54 Glatiramer Acetate 54 MAb therapy 54 Zelrix 54 VIBATIV 54 bardoxolone methyl 54 Paliperidone ER 54 GEM OS1 54 Phase #b/#a 54 Tyzeka 54 Phase 1b clinical 54 Trovax